DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

• Status: Unknown status
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. DC-CIK immunotherapy has been proved to improve survival in cancer patients, but its role in stage III colorectal cancer patients stains unclear. The investigators study will focus on the efficacy and safety of DC-CIK immunotherapy plus chemotherapy in the adjuvant treatment of stage III colorectal cancer, compared with chemotherapy alone.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
• Treatments: Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Stage III colon cancer

• Undergone complete resection of primary tumor

• Completed standard adjuvant chemotherapy

• ECOG performancer status 0-2

• Adequate hematologic, hepatic and renal functions

Exclusion Criteria:

• HIV positive or other Immunodeficiency disease

• Uncontrolled hypertension

• History of recent cancers in the past 5 years

• Patients with previous or concurrent malignancy or any anti-cancer therapy

• Patients who were allergic to platinum drugs or fluorouracil

• Pregnant patients